Table 2 Baseline patient characteristics by CNS-IPI score
High risk | Intermediate risk | Low risk | P value | |
|---|---|---|---|---|
(n = 25) | (n = 97) | (n = 14) | ||
Age | 0.0014 | |||
Median | 69 | 69 | 56.5 | |
Range | (55.0–83.0) | (19.0–87.0) | (24.0–79.0) | |
Clinical stage | < 0.0001 | |||
2 | 0 (0.0%) | 13 (13.4%) | 6 (42.9%) | |
3 | 0 (0.0%) | 25 (25.8%) | 4 (28.6%) | |
4 | 25 (100.0%) | 59 (60.8%) | 4 (28.6%) | |
Cell of origin | 0.2353 | |||
GCB | 7 (28.0%) | 47 (48.5%) | 5 (35.7%) | |
Non-GCB | 10 (40.0%) | 35 (36.1%) | 5 (35.7%) | |
NA | 8 (32.0%) | 15 (15.5%) | 4 (28.6%) | |
LDH above ULN | <0.0001 | |||
No | 2 (8.0%) | 45 (46.4%) | 13 (92.9%) | |
Yes | 23 (92.0%) | 52 (53.6%) | 1 (7.1%) | |
Extranodal sites | <0.0001 | |||
0 or 1 | 2 (8.0%) | 79 (81.4%) | 14 (100.0%) | |
>1 site | 23 (92.0%) | 18 (18.6%) | 0 (0.0%) | |
Performance status | <0.0001 | |||
0 | 5 (20.0%) | 45 (46.4%) | 10 (71.4%) | |
1 | 9 (36.0%) | 47 (48.5%) | 4 (28.6%) | |
2 | 11 (44.0%) | 5 (5.2%) | 0 (0.0%) | |
CNS prophylaxis | <0.0001 | |||
No | 14 (56.0%) | 88 (90.7%) | 14 (100.0%) | |
Yes | 11 (44.0%) | 9 (9.3%) | 0 (0.0%) | |
